Response to Interleukin-1 Blockade With Anakinra in Black and White Americans With ST-Segment Elevation Myocardial Infarction.
Response to Interleukin-1 Blockade With Anakinra in Black and White Americans With ST-Segment Elevation Myocardial Infarction.
复制标题
患有 ST 段抬高型心肌梗塞的美国黑人和白人对使用阿那白滞素 (Anakinra) 阻断 Interleukin-1 的反应。
DOI：
10.1016/j.amjcard.2023.08.175
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Keen,L
中科院分区：
文献类型：
--
作者：
Corna,Giuliana;Golino,Michele;Moroni,Francesco;DelBuono,MarcoGiuseppe;Talasaz,AzitaH;Decotto,Santiago;Mbualungu,James;Trankle,CoryR;Thomas,GeorgiaK;Markley,Roshanak;Canada,JustinM;Turlington,Jeremy;Agatiello,CarlaR;Keen,L
Funding: The VCUART2 study was supported by an American Heart Association Scientist Development grant 10SDG 3030051 and a Presidential Research Incentive Program of the Virginia Commonwealth University to Dr. Abbate and by an Institutional National Institute of Health K12 award KL2RR031989 to Dr. Van Tassell. The VCUART3 study was supported by a grant from the National Institutes of Health (1R34HL121402-01) to Dr. Abbate and Dr. Van Tassell. Swedish Orphan Biovitrum provided anakinra and matching placebo for VCUART3. Disclosures: Dr Abbate and Dr Van Tassell have served as consultants to Swedish Orphan Biovitrum LLC in the past. Dr. Abbate has also served as a consultant to Cardiol Therapeutics, Kiniksa Pharmaceuticals, Implicit Biosciences, Novo Nordisk, Olatec, and R-Pharm. The remaining authors have no disclosures to report.
